High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab.

However, when looking at PD-L1 expression, comparing expression less than 1% or greater than or equal to 1% did not significantly impact pneumonitis events, but there were seven pneumonitis events (38.7%) at 1 year with PD-L1 expression less than 50% versus 2 pneumonitis events (10.5%) at 1 year with PD-L1 expression greater than or equal to 50% with a p value of 0.053 that approached significance.

also in 8,237 other papers